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Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can
potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal
stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators in vitro.
Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions in vivo. Herein, we
report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned
medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival
benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell
numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic
reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate
using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the
injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in
liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic
cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all
chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this
fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of
an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic
modality for FHF.
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Hepatic Failure. PLoS ONE 2(9): e941. doi:10.1371/journal.pone.0000941
INTRODUCTION
Clinical trials testing the efficacy of bioartificial liver support in
treating fulminant hepatic failure (FHF) have provided some
promising results, yet the current generation of devices has not
demonstrated sufficient efficacy and reliability for routine use,
primarily due to a lack of a functionally stable, human hepatocyte
source [1]. We have previously shown that immunomodulation via
interleukin-1receptorantagonismintheformof:(a)therecombinant
protein, (b) adenoviral vector gene therapy, or (c) transfected
hepatocytes seeded in an extracorporeal device, can provide
a survival benefit in an animal model of FHF [2,3]. However, due
to concerns associated with gene transfer in vivo or ex vivo and the
expense of recombinant protein production, we sought to identify
a natural human ‘‘cellular equivalent’’ of immunomodulation that
could be incorporated into bioartificial liver assist devices.
Within the bone marrow space multipotent stromal cells, also
referred to as mesenchymal stem cells (MSCs), are known to be the
precursor cell for stromal tissues that support hematopoiesis [4].
The immunomodulatory function of MSCs was first reported after
it was observed that they could evade immunosurveillance after
cell transplantation [5]. This ability of MSCs to alter an immune
response has been exploited for therapeutic purposes as demon-
strated by the case of a patient suffering from steroid-refractory
graft-versus-host disease who was successfully treated by the
infusion of haploidentical MSCs [6]. In vitro studies have
subsequently shown that MSCs actively inhibit the function of
several immune cells through secreted cytokines, growth factors
and enzymatic action, although controversy exists on the identity
of the responsible mediators [7,8,9,10,11]. The fortification of the
soluble microenvironment by MSCs can also affect non-hemato-
poietic cells as well. MSCs used for cellular cardiomyoplasty after
an ischemic event revealed that MSC-derived soluble molecules
inhibited hypoxia-induced apoptosis of cardiomyocytes during the
acute phase of injury resolution [12,13]. Taken together, these
studies indicate that MSCs can independently affect immune and
tissue cells by paracrine means.
On this basis, we hypothesized that the paracrine function of
MSCs may be of therapeutic value when used in the setting of
acute organ failure, wherein parenchymal cell loss is integrated
with a local and systemic inflammatory response. Here, we report
a significant survival benefit in the treatment of FHF after
intravenous delivery of MSC biomolecules in the form of bolus
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extracorporeal bioreactor (MSC-EB). The survival benefit of
MSC-CM was a function of the cell mass used for media
conditioning and was found to have an optimum. Histological
analysis of liver tissue after MSC-CM treatment showed a remark-
able reduction in infiltrating leukocytes as well protection of
hepatobiliary pathological changes. In addition, we show that
MSC-CM actively promotes the emigration of adoptively trans-
ferred leukocytes from the injured liver. Finally, we performed
a proteomic screen of the MSC secretome and detected high levels
of potent chemotactic cytokines. Fractionation of MSC-CM based
on affinity to heparin sulfate, a known ligand for all chemokines,
revealed that the therapeutic activity of MSC-CM was restricted to
the heparin bound fraction, further supporting the role of
chemokines as responsible mediators.
RESULTS
MSC-derived components reverse FHF
We first assessed various MSC treatment modalities such as cell
transplantation, delivery of cellular lysates or conditioned medium
to assess the most efficacious therapy. Sprague-Dawley rats were
intraperitoneally administered a total of two injections of 1.2 g/kg
of a hepatotoxin, D-galactosamine (Gal-N), each separated by
12 hours [14]. With this regimen of liver failure induction, we
have previously shown that death occurs 36–72 hours after
injection of the first dose and is associated with significant
hepatocellular necrosis concomitant with leukocyte infiltration and
an increase of inflammatory cytokines in liver tissue. Animals were
treated 24 hours after FHF induction with intravenous injections
of whole cells or cell lysates. No significant benefit was seen after
the intravenous infusion of 2610
6 human MSCs 24 hours post-
induction, which is most likely due to poor engraftment,
entrapment in the alveolar capillary bed and/or immune rejection
of the cells (Fig. 1). In contrast, treatment with cellular lysates,
derived from the same cell mass used for transplantation, showed
an increased survival trend compared to vehicle (P,0.47) and
fibroblast lysate (P,0.36) controls.
We then determined if the efficacy observed with lysates could be
reproduced by using the secreted molecules from MSCs. A
longitudinal study using MSC-CM from the same cell mass (i.e.,
2610
6 human MSCs) revealed a distinct survival benefit compared
to vehicle (P,0.032) and fibroblast (P,0.026) concentrated medium
(Fig. 2A). In addition, we monitored 72 hour survival of FHF-
induced rats as a function of MSC mass from which medium was
conditioned (Fig. 2B). Interestingly, the effect of MSC concentrate
was abrogated at higher cell masses indicating a therapeutic window
of effectiveness. Moreover, the observation that xenogeneic MSC
lysates and supernatants decreased animal mortality suggests that
these factors can cross species barriers.
Combined metabolic and secretory function in
MSC-EB support provide hepatoprotection and
survival benefit
Based on these results, we then developed a MSC-EB to combine
the effectiveness of intracellular and secreted molecules of MSCs
in a single device. Animals were treated 24 hours after FHF
induction with a human MSC-EB connected to the systemic
Figure 1. Infusion of MSC lysate provides a survival trend in an
animal model of FHF. Sprague-Dawley rats were administered lethal
intraperitoneal injections of a hepatotoxin. Animals were treated with
i.v. injections of MSCs, or MSC lysates from the same cell mass (2610
6
cells). Controls received vehicle or NIH 3T3-J2 fibroblast components.
Kaplan-Meier survival analysis of Gal-N administered rats treated with
cell transplants or lysates. Time points of interventions are stated above
survival plots. Results are cumulative data of two independent
experiments (N=8 per each group) using different batches of MSCs.
P-value determined by Log Rank Test.
doi:10.1371/journal.pone.0000941.g001
Figure 2. MSC-CM reverses FHF in a cell mass-dependent manner. (A) Kaplan-Meier survival analysis of Gal-N administered rats treated with
concentrated MSC-CM. (B) Dose response of animal survival 72 hours after liver failure induction as a function of MSC mass from which MSC-CM was
derived. Controls received vehicle or fibroblast conditioned medium (fibroblast-CM). Time points of interventions are stated above survival plots.
Results for both panels are cumulative data of two independent experiments using different batches of MSC-CM (N=8 per each group). P-value
determined by Log Rank Test.
doi:10.1371/journal.pone.0000941.g002
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(fibroblast-EB) and acellular (acellular-EB) bioreactors served as
controls. After 10 hours of extracorporeal perfusion, animals were
taken off assist support and monitored for survival. Plasma was
obtained at the start of, and 24 hours after, bioreactor treatment
and analyzed for hepatocyte enzyme release. Liver serologies,
including aspartate aminotransferase (P,0.02) and alanine
aminotransferase (P,0.001) were improved in animals treated
with the MSC-EB (Fig. 3A). These data demonstrate a hepatopro-
tective effect of device therapy as shown by the reduction in
biochemical markers of hepatocyte death. More importantly, 71%
of animals treated with the MSC-EB survived, compared to 14%
(Fig. 3B) in both acellular (P,0.037) and fibroblast controls
(P,0.05).
MSC-CM therapy inhibits panlobular leukocyte
invasion, bile duct duplication and hepatocellular
death
In order to determine histopathological changes after MSC-CM
therapy we used a sub-lethal regimen Gal-N to induce acute
liver injury, thereby ensuring survival in our control-treated
group for comparison. It should be noted that even at this Gal-N
dose, mortality occurred in a vehicle-treated group (N=1)
confirming that the extent of injury in this model can still be
fatal. Gal-N injured rats were treated with vehicle (N=4) or MSC-
CM (N=4) 24 hours after injury and their livers were harvested
36 hours thereafter for pathological analysis. Microscopic evalu-
ation of liver tissue from vehicle treated rats revealed profound
hepatocellular apoptosis, bile duct duplication and panlobular
mononuclear leukocyte infiltration with cytoplasmic vacuolization
and severe distortion of tissue architecture (Fig. 4A,C). MSC-CM
treated rats showed no signs of disseminated inflammation
(Fig. 4B), although minor periportal infiltration with edema and
fibrin deposition consistent with tissue repair was observed
(Fig. 4D).
MSC-CM treatment alters immune cell migration to
the liver
We hypothesized that one potential explanation for the lack of
panlobular leukocyte infiltration may be that MSC-CM treatment
may divert immune cell migration away from an inflamed, target
organ. To test this theory, we adoptively transferred radiolabeled
leukocytes, directly after MSC-CM or vehicle treatment, into Gal-
N (0.6 g/kg) injured rats and monitored leukocyte trafficking using
single photon emission computed tomography (SPECT) over time
(Fig. 5A). Qualitatively, more leukocytes were seen migrating to
the liver in vehicle treated animals over time (Fig. 5E–G). In
contrast, there was a distinct decrease in signal intensity in the liver
of MSC-CM treated animals over time (Fig. 5B–D). These results
suggest that there was a selective pressure upon leukocytes to
emigrate from the liver due to MSC-CM, unlike control conditions
where leukocytes eventually migrated to the injured organ. These
data support our hypothesis that altered leukocyte migration may
be a potential target of MSC-CM therapy, however other
explanations cannot be ruled out without more comprehensive
investigations.
MSC-CM is composed of many chemokines that
correlate with therapeutic activity
In an effort to understand the molecular mediators of the observed
effects of MSC therapy, we examined MSC-CM using a high-
density protein array. MSC-CM contained 69 of the 174 proteins
assayed (Fig. 6A), which included a broad spectrum of molecules
involved in immunomodulation and liver regeneration. Cluster
analysis revealed that a large fraction (30%) of MSC-CM was
composed of chemokines (Fig. 6B), many of which were expressed
at very high relative levels. We decided to fractionate MSC-CM
based on functionality using affinity-based methods rather than
other arbitrary molecular criteria such as size or hydrophobicity.
MSC-CM was passed over an affinity column impregnated with
heparin sulfate, a known ligand for all chemokines and separated
into bound and unbound fractions. Each fraction was infused into
FHF-induced rats with overall survival as the study endpoint. We
observed that the therapeutic activity of MSC-CM was restricted
to the heparin bound fraction, providing a strong correlation
between chemokines and the survival benefit after MSC-CM
infusion in FHF-induced rats (Fig. 6C).
Figure 3. MSC-EB support reduces liver injury biomarkers and
increases survival. Animals were treated with an MSC-EB, using a 3T3
fibroblast-based bioreactor (fibroblast-EB) and an acellular bioreactor
(acellular-EB) as controls. (A) Serum biomarkers of liver injury, aspartate
aminotransferase and alanine aminotransferase preceding and 24 hours
after treatment with a MSC-EB (n=5) or an acellular-EB (n=3). Due to
mortality, n=1 in the acellular group after treatment. (B) Kaplan-Meier
survival analysis of Gal-N administered rats treated with EBs. Time
points of interventions are stated above survival plots. Each result for
(B) was an independent experiment using different batches of MSCs. P-
value determined by student’s t-test analysis for panel (A). P-value
determined by Log Rank Test for panel (B).
doi:10.1371/journal.pone.0000941.g003
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Our findings demonstrate that MSC-derived molecules can
protect against hepatocyte death and increase survival in Gal-N
induced FHF. Specifically, we have shown that an intravenous
bolus of MSC-CM during active disease can reverse organ failure.
The efficacy of MSC-CM was found to be a function of the cell
mass from which media were conditioned suggesting important
pharmacological aspects of this treatment. Treatment with a MSC-
EB, which combined both the secretory and metabolic functions of
MSCs in a single device, provided the greatest benefit in survival
and potentially illustrates a platform to study stem cell function
and the bone marrow microenvironment ex vivo. These results are
significant because we have identified a non-hepatic source of
human cells with minimal metabolic demands that can be
expanded to clinical scale for liver assist devices and shown that
MSC treatment can cross species barriers.
Histological evaluation of liver tissue after MSC-CM treatment
provided initial insight into the cellular targets of therapy. A
striking reduction in mononuclear leukocytes was seen post-
treatment, suggesting that MSC-CM may inhibit the ability of
immune cells to invade and/or function within the injured tissue.
Using SPECT imaging of adoptively transferred leukocytes, we
provide evidence showing altered immune cell migration after
MSC-CM treatment supporting our hypothesis that MSC-CM
modulated the immune response to organ injury. Interestingly, it
appears that MSC-CM did not divert leukocyte trafficking from
the injured site initially, but rather induced a selective emigration
of homed leukocytes out of the organ. In addition, we observed
prevention of hepatocyte apoptosis and inhibition of bile duct
duplication after MSC-CM treatment. Further investigation is
needed to determine if these are direct or indirect effects of MSC-
CM as well as the temporal sequence of histological changes to
evaluate which processes are the primary targets of MSC-CM and
which are merely secondary effects.
Proteomic analysis of MSC-CM revealed a broad spectrum of
molecules involved in immunomodulation and liver regeneration.
Powered by our knowledge that MSC-CM specifically alters
leukocyte migration, we first looked at chemotactic cytokines as
potential mediators of the therapeutic effect of MSC-CM.
Approximately 30% of MSC-CM was composed of relatively
high levels of potent chemokines that, when fractionated based on
heparin binding affinity, correlated with the therapeutic activity of
MSC-CM. We are currently testing individual chemokines and
combinations thereof to demonstrate a casual relationship.
Moreover, since any positively charged molecule can ionically
interact with heparin sulfate, we cannot rule out other heparin
binding compounds such hepatocyte growth factor within the
screen of MSC-CM.
Figure 4. MSC-CM treatment inhibits immune cell infiltration and hepatobiliary cell change in Gal-N injured liver tissue. Representative H&E
histology sections of liver tissue from Gal-N injured rats 36 hours post-treatment with vehicle (A,C) or MSC-CM (B, D). Scale bars are indicated on the
micrographs. Images (A, B) and (C,D) are captured 106and 206magnification, respectively.
doi:10.1371/journal.pone.0000941.g004
Figure 5. Alteration in leukocyte migration after MSC-CM treatment.
(A) Experimental design of adoptive transfer study. Gal-N injured rats
were treated with vehicle or MSC-CM followed by infusion of In
111-
labeled leukocytes. SPECT images were acquired at t=0, 3, and 24 hr.
for MSC-CM (B–D) and vehicle (E–G) treated rats, respectively.
doi:10.1371/journal.pone.0000941.g005
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metabolic functions of MSCs to derive a new class of immu-
notherapeutics. Whether this strategy of MSC-CM or MSC-EB
therapy is a relevant means of treatment for other organ failure
and inflammatory conditions should be experimentally explored.
MATERIALS AND METHODS
Materials were purchased from Sigma-Aldrich, St. Louis, MO
unless otherwise stated.
Cell Culture
Human MSCs were isolated from commercially available bone
marrow aspirates (Clonetics-Poietics, Walkersville, MD) and
grown and characterized as previously reported [15]. Cells were
used for experiments during passages 3-7. NIH 3T3-J2 fibroblasts
were a kind gift from Dr. Howard Green and cultured according
to donor’s protocols.
Preparation and delivery of cells, cell lysates and
conditioned medium
Cellular lysates were prepared by sonication (VWR Scientific,
West Chester, PA). The dose of sonicated cells administered was
2610
6 cells per subject, which represented the same cell mass used
for extracorporeal bioreactor or cell transplant experiments.
Conditioned medium was prepared by collecting serum-free
medium (supplemented with 0.05% bovine serum albumin to
prevent protein aggregation) after 24 hour culture of different cell
masses. The majority of experiments were performed with the
optimal cell mass of 2610
6 cells. The medium was then
concentrated, approximately 25 fold, using ultrafiltration units
(Amicon Ultra-PL 3, Millipore, Bedford, MA, USA) with a 3 kDa
molecular weight cut-off. For fractionation experiments, concen-
trated medium was passed over a heparin-agarose column and the
flow-through and eluted fractions were collected and reconcen-
trated using the same ultrafiltration system. A total volume of
500 ml containing cells, cellular lysates, vehicle (PBS) only or
900 ml of conditioned medium was infused in the penile vein
24 hours after induction of FHF using the same anaesthesia
protocol described for the cannulation procedure.
Liver Failure Induction and Extracorporeal
Bioreactor Support
The induction of fulminant hepatic failure and extracorporeal
device operation is previously reported [2]. Briefly, male Sprague-
Dawley rats weighing between 280 and 370 grams were
Figure 6. MSC-CM is composed of high levels of chemokines that correlate with survival benefit seen in FHF. Serum-free MSC-CM was analyzed
using an antibody array for 174 specified proteins. (A) Densiometry of spotted antibody array results. Data are presented as spot intensity relative to
the negative control and normalized to positive control. (B) Pie chart showing cluster analysis of MSC secreted proteins based on reported function.
MSC-CM was fractionated over a heparin-agarose column into heparin bound and unbound fractions. (C) Kaplan-Meier survival analysis of Gal-N
administered rats treated with the (+) heparin MSC-CM and (2) heparin MSC-CM. Time points of interventions are stated above survival plots. Results
for (C) are cumulative data of two independent experiments using different batches of MSC-CM (N=8 per each group). P-value determined by Log
Rank Test.
doi:10.1371/journal.pone.0000941.g006
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xylazine at 110 and 0.4 mg/kg, respectively. The left carotid
artery and right jugular vein were cannulated and the animal was
placed in a metabolic cage. Twenty-four hours later, 1.2 g/kg Gal-
N freshly dissolved in physiological saline and adjusted to pH 7.3
with 1 N NaOH was injected i.p., followed by a second equal
injection 12 hours later. Twenty-four hours after the first injection
of Gal-N, the arterial and venous lines were connected to an
extracorporeal circuit. Plasma was separated using a plasma
separator (MicroKros, pore size 0.2 micron). Plasma was perfused
through the polycarbonate, flat-plate bioreactor and subsequently
reunited with the cellular components of the blood and returned to
the animal. The extracorporeal bioreactor was operated for
10 hours. Animals that died during reactor operation and failed to
receive adequate treatment (MSC-EB, N=3 and Fibroblast-EB,
N=2) were censored from analysis. Animal survival was
monitored every 12 hours. Plasma or whole blood was analyzed
for liver injury biomarkers using a microfluidic metabolic assay
(Picollo, Abaxis, Union City, CA).
Liver Histology
Liver tissue was harvested from rats induced with a sub-lethal
regimen of Gal-N (0.6 g/kg), 36 hours after treatment with MSC-
CM. Tissue was fixed in 10% buffered formalin, embedded in
paraffin, sectioned to 6-mm thickness, and stained with hematoylin
and eosin.
Adoptive transfer of radiolabeled leukocytes
Leukocytes were isolated from whole rat blood by NH4Cl
erythrocyte lysis. Cells were pelleted, washed once with PBS and
resuspended in 0.9% saline containing the In
111 oxine isotope (GE
Healthcare Biosciences Corp., Piscataway, NJ). Cells were labeled
at 92% efficiency with high viability. Approximately 15610
6 cells
were infused into the penile vein of Gal-N injured (0.6 g/kg)
directly after treatment with vehicle or MSC-CM. SPECT images
were captured using a M.CAM gamma camera setup (Siemens
Medical Systems, Malvern, PA) at 0, 3 and 24 hours after
leukocyte infusion.
Protein array of MSC supernatants
Supernatants were prepared by collecting serum-free medium
after 24 hour culture of approximately 2610
6 MSCs. These were
analyzed for a panel of specified proteins using an antibody array
(RayBio Human Cytokine Antibody Array C Series 2000,
RayBiotech Inc., Norcross, GA) as specified by the vendor.
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